Altre lingue Regencell Bioscience Holdings Limited

Azioni

RGC

KYG7487R1002

Mercato chiuso - Nasdaq Altri mercati azionari 22:30:00 03/05/2024			Variaz. 5gg	Var. 1 gen.
5,33 ^USD	-17,87%		-0,37%	-49,24%

2023	Regencell Bioscience Holdings Limited riporta i risultati degli utili per l'intero anno conclusosi il 30 giugno 2023	CI
2023	Regencell Bioscience Holdings Limited riporta i risultati degli utili per il semestre conclusosi il 31 dicembre 2022	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Regencell Bioscience : Resignation of Yi-Chung Chao as Director - Form 6-K	02/01
Regencell Bioscience : Form of Letter of Lock-up Undertaking - Form 6-K	15/12
Regencell Bioscience Holdings Limited Reports Earnings Results for the Full Year Ended June 30, 2023	27/10/23
Regencell Bioscience : Announces First Half 2023 Management Financial Results - Form 6-K	15/06/23
Regencell Bioscience Holdings Limited Reports Earnings Results for the Half Year Ended December 31, 2022	15/06/23
Regencell Bioscience : Changes in Registrant’s Certifying Accountant - Form 6-K	17/03/23
Regencell Bioscience : Appointment of Chief Business Officer - Form 6-K	28/02/23
Regencell Bioscience Holdings Limited Promotes Yat-Pui Au from Senior Vice President to Chief Business Officer	28/02/23
Regencell Bioscience : Letter of Lock-Up Undertaking - Form 6-K	04/01/23
Regencell Bioscience : Resignation of Chief Medical Officer - Form 6-K	22/12/22
Regencell Bioscience Holdings Limited Announces the Resignation of Yi-Chung Chao as Chief Medical Officer, with Effect from December 28, 2022	22/12/22
Regencell Bioscience Holdings Limited Reports Earnings Results for the Full Year Ended June 30, 2022	31/10/22
Regencell Bioscience’s Standardized Formulae Are Shown to Reduce ADHD and ASD Symptoms in the Interim Results of its Second Efficacy Trial	12/09/22
Regencell Bioscience Holdings Limited Announces its Standardized Formulae Shows Reduce ADHD and ASD Symptoms in Interim Results of its Second Efficacy Trial	12/09/22
Regencell Bioscience : Announces First Half 2022 Management Financial Results - Form 6-K	02/06/22
Regencell Bioscience Holdings Limited Reports Earnings Results for the Half Year Ended December 31, 2021	02/06/22
Regencell Bioscience Announces Additional EARTH Efficacy Trial Results Corroborating Effectiveness of its Investigational Liquid-Formula RGC-COV19TM in Eliminating Mild to Moderate COVID-19 Symptoms within the 6-Day Treatment Period	18/05/22
Regencell Bioscience Holdings Limited Announces Additional Earth Efficacy Trial Results Corroborating Effectiveness of Its Investigational Liquid-Formula Rgc-Cov19tm in Eliminating Mild to Moderate Covid-19 Symptoms Within the 6-Day Treatment Period	18/05/22
Regencell Bioscience Holdings Limited Announces Over $5 Million Ordinary Share Purchases by CEO	16/05/22
Regencell Bioscience Holdings Limited Announces Over $5 Million Ordinary Share Purchases by CEO	16/05/22

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Regencell Bioscience Holdings Limited

Azioni

RGC

KYG7487R1002

Altre lingue

Filtri